Mar 26, 2019
The mission at The University of Texas MD Anderson Cancer is to eradicate cancer, which remains a major cause of mortality worldwide. It is the second leading cause of death in the United States and globally, claiming more lives than malaria, HIV/AIDs and tuberculosis combined.
Still, the news about cancer is not all grim, given the incredible advances we have witnessed in cancer treatments over the past several years, highlighted by targeted therapies and novel immunotherapies, including immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy and cancer vaccines.
Despite the recent success, improvements in drug design are of little value for patients if novel therapeutics cannot be advanced from the bench to the bedside both efficiently (minimising the failure rates to keeps costs down) and rapidly (to provide transformative, life-saving medications to as many patients as possible, as soon as possible).
Original article by Dr Phil Jones,
VP for Therapeutics Discovery and Head of Drug Discovery for the
Institute of Applied Cancer Science at The University of Texas MD
Anderson Cancer Center
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: